Evolent Health Analyst Price Targets - Benzinga

Evolent Health Inc

EVHNYSE

Trade with Public

Trade with Public

$4.48

0.184.19%

Ult. Agg.: Nov 2, 11:33 AM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

© 2026 Benzinga | All Rights Reserved

Evolent Health Analyst Price Targets - Benzinga

Evolent Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Evolent Health (EVH).

Price Target Range — 12 Quarters

Analyst Consensus — 16 Analysts

3S.Buy

11Buy

2Hold

Consensus RatingBuy# Analysts16Avg. Consensus PT$11Upside to Avg. PT+138.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 18, 2026	JP Morgan	John Stansel	PT Raise	Overweight	$5→$6
Aug 17, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$5→$6
Aug 12, 2026	Truist Securities	Jailendra Singh	PT Cut	Hold	$7→$6
Aug 11, 2026	Citigroup	Daniel Grosslight	Upgrade	Neutral→Buy	$7→$6
Aug 10, 2026	Canaccord Genuity	Richard Close	PT Cut	Buy	$7→$6
Jul 28, 2026	TD Cowen	Charles Rhyee	PT Cut	Buy	$8→$5
Jul 23, 2026	Citigroup	Daniel Grosslight	Downgrade	Buy→Neutral	$6→$7
Jul 21, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$6→$7
Jun 30, 2026	Truist Securities	Jailendra Singh	Downgrade	Buy→Hold	$7
Jun 12, 2026	Truist Securities	Jailendra Singh	PT Raise	Buy	$6→$7
May 15, 2026	Citigroup	Daniel Grosslight	PT Raise	Buy	$4→$6
May 12, 2026	Canaccord Genuity	Richard Close	PT Raise	Buy	$4→$6
May 7, 2026	Needham	Matthew Shea	PT Raise	Buy	$4→$5
Mar 2, 2026	Oppenheimer	Michael Wiederhorn	PT Cut	Outperform	$12→$6
Feb 26, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$6→$4
Feb 26, 2026	UBS	Kevin Caliendo	PT Cut	Buy	$10→$5
Feb 26, 2026	Truist Securities	Jailendra Singh	PT Cut	Buy	$10→$6
Feb 25, 2026	Needham	Matthew Shea	PT Cut	Buy	$15→$4
Feb 25, 2026	RBC Capital	Ryan Halsted	PT Cut	Sector Perform	$5→$3
Feb 25, 2026	Keybanc	Matthew Gillmor	Downgrade	Overweight→Sector Weight	—

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $6

JP Morgan analyst John Stansel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $5 to $6.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Evolent Health, Raises Price Target to $6

TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Evolent Health, Lowers Price Target to $6

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Hold and lowers the price target from $7 to $6.

Benzinga Newsdesk

PRO
Citigroup Upgrades Evolent Health to Buy, Lowers Price Target to $6

Citigroup analyst Daniel Grosslight upgrades Evolent Health (NYSE:EVH) from Neutral to Buy and lowers the price target from $6.75 to $6.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $6

Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $7 to $6.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Evolent Health, Lowers Price Target to $5

TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $8 to $5.

Benzinga Newsdesk